Statera Biopharma Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Statera Biopharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Statera Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Statera Biopharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 593.9 K |
Statera |
Statera Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Statera Biopharma on December 20, 2024 and sell it today you would earn a total of 100.00 from holding Statera Biopharma or generate -100.0% return on investment over 90 days. Statera Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Statera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Statera Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Statera Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Statera Biopharma, and traders can use it to determine the average amount a Statera Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| STAB |
Based on monthly moving average Statera Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Statera Biopharma by adding Statera Biopharma to a well-diversified portfolio.
Statera Biopharma Fundamentals Growth
Statera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Statera Biopharma, and Statera Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Statera Pink Sheet performance.
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 1.49 M | ||||
| EBITDA | (97.27 M) | ||||
| Cash And Equivalents | 506.1 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 10.62 M | ||||
| Debt To Equity | 0.23 % | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (28.19 M) | ||||
| Earnings Per Share | (0.76) X | ||||
| Total Asset | 21.17 M | ||||
Things to note about Statera Biopharma performance evaluation
Checking the ongoing alerts about Statera Biopharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Statera Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Statera Biopharma is not yet fully synchronised with the market data | |
| Statera Biopharma has some characteristics of a very speculative penny stock | |
| Statera Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K. | |
| Statera Biopharma currently holds about 506.1 K in cash with (28.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of Statera Biopharma outstanding shares are owned by corporate insiders |
- Analyzing Statera Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Statera Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Statera Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Statera Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Statera Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Statera Biopharma's pink sheet. These opinions can provide insight into Statera Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |